NASDAQ: LVTXLava Therapeutics Nv Stock
$2.71-0.12 (-4.24%)
Updated Apr 19, 2024
LVTX Price
$2.71
Fair Value Price
-$2.51
Market Cap
$71.24M
52 Week Low
$1.13
52 Week High
$6.47
P/E
-1.59x
P/B
1.28x
P/S
5.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.36M
Earnings
-$46.64M
Gross Margin
48.6%
Operating Margin
-659.85%
Profit Margin
-620.1%
Debt to Equity
0.99
Operating Cash Flow
-$43M
Beta
0.35
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LVTX Overview
LAVA Therapeutics N.V. offers Gammabody platform, a portfolio of novel bispecific antibodies that engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. The company's lead clinical-stage candidates are LAVA-051, in Phase 1/2a clinical trials for blood cancers (chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia), and LAVA-1207, in Phase 1/2a clinical trials for metastatic castration-resistant prostate cancer. LAVA Therapeutics was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LVTX ($2.71) is overvalued by 208.1% relative to our estimate of its Fair Value price of -$2.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LVTX ($2.71) is not significantly undervalued (208.1%) relative to our estimate of its Fair Value price of -$2.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LVTX due diligence checks available for Premium users.
Be the first to know about important LVTX news, forecast changes, insider trades & much more!
LVTX News
Valuation
LVTX fair value
Fair Value of LVTX stock based on Discounted Cash Flow (DCF)
Price
$2.71
Fair Value
-$2.51
Undervalued by
208.10%
LVTX ($2.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LVTX ($2.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LVTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.59x
Industry
15.81x
Market
40.51x
LVTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
5.74x
LVTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LVTX's financial health
Profit margin
Revenue
$392.2k
Net Income
-$7.2M
Profit Margin
-1,840.8%
LVTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LVTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$113.0M
Liabilities
$56.1M
Debt to equity
0.99
LVTX's short-term assets ($107.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LVTX's short-term assets ($107.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.2M
Investing
-$9.7M
Financing
-$200.0k
LVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LVTX vs Biotech Stocks
Lava Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.